196 related articles for article (PubMed ID: 20087354)
1. Expansion of anti-AFP Th1 and Tc1 responses in hepatocellular carcinoma occur in different stages of disease.
Behboudi S; Alisa A; Boswell S; Anastassiou J; Pathan AA; Williams R
Br J Cancer; 2010 Feb; 102(4):748-53. PubMed ID: 20087354
[TBL] [Abstract][Full Text] [Related]
2. Analysis of CD4+ T-Cell responses to a novel alpha-fetoprotein-derived epitope in hepatocellular carcinoma patients.
Alisa A; Ives A; Pathan AA; Navarrete CV; Williams R; Bertoletti A; Behboudi S
Clin Cancer Res; 2005 Sep; 11(18):6686-94. PubMed ID: 16166448
[TBL] [Abstract][Full Text] [Related]
3. Cirrhotic patients with or without hepatocellular carcinoma harbour AFP-specific T-lymphocytes that can be activated in vitro by human alpha-fetoprotein.
Hanke P; Rabe C; Serwe M; Böhm S; Pagenstecher C; Sauerbruch T; Caselmann WH
Scand J Gastroenterol; 2002 Aug; 37(8):949-55. PubMed ID: 12229971
[TBL] [Abstract][Full Text] [Related]
4. Value of serum anti-p53 antibodies as a prognostic factor in Egyptian patients with hepatocellular carcinoma.
Atta MM; el-Masry SA; Abdel-Hameed M; Baiomy HA; Ramadan NE
Clin Biochem; 2008 Oct; 41(14-15):1131-9. PubMed ID: 18616935
[TBL] [Abstract][Full Text] [Related]
5. AFP-specific CD4+ helper T-cell responses in healthy donors and HCC patients.
Evdokimova VN; Liu Y; Potter DM; Butterfield LH
J Immunother; 2007; 30(4):425-37. PubMed ID: 17457217
[TBL] [Abstract][Full Text] [Related]
6. Distinct tumour antigen-specific T-cell immune response profiles at different hepatocellular carcinoma stages.
Zang C; Zhao Y; Qin L; Liu G; Sun J; Li K; Zhao Y; Sheng S; Zhang H; He N; Zhao P; Wang Q; Li X; Peng Y; Dong T; Zhang Y
BMC Cancer; 2021 Sep; 21(1):1007. PubMed ID: 34496797
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the correlation between serum prolidase and alpha-fetoprotein levels in patients with hepatocellular carcinoma.
Ilikhan SU; Bilici M; Sahin H; Akca AS; Can M; Oz II; Guven B; Buyukuysal MC; Ustundag Y
World J Gastroenterol; 2015 Jun; 21(22):6999-7007. PubMed ID: 26078578
[TBL] [Abstract][Full Text] [Related]
8. Lentivirally engineered dendritic cells activate AFP-specific T cells which inhibit hepatocellular carcinoma growth in vitro and in vivo.
Liu Y; Butterfield LH; Fu X; Song Z; Zhang X; Lu C; Ding G; Wu M
Int J Oncol; 2011 Jul; 39(1):245-53. PubMed ID: 21491085
[TBL] [Abstract][Full Text] [Related]
9. Unmasking of alpha-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization.
Ayaru L; Pereira SP; Alisa A; Pathan AA; Williams R; Davidson B; Burroughs AK; Meyer T; Behboudi S
J Immunol; 2007 Feb; 178(3):1914-22. PubMed ID: 17237442
[TBL] [Abstract][Full Text] [Related]
10. Association of serum level of growth differentiation factor 15 with liver cirrhosis and hepatocellular carcinoma.
Liu X; Chi X; Gong Q; Gao L; Niu Y; Chi X; Cheng M; Si Y; Wang M; Zhong J; Niu J; Yang W
PLoS One; 2015; 10(5):e0127518. PubMed ID: 25996938
[TBL] [Abstract][Full Text] [Related]
11. Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use.
Giannini EG; Sammito G; Farinati F; Ciccarese F; Pecorelli A; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Cabibbo G; Felder M; Gasbarrini A; Sacco R; Foschi FG; Missale G; Morisco F; Svegliati Baroni G; Virdone R; Trevisani F;
Cancer; 2014 Jul; 120(14):2150-7. PubMed ID: 24723129
[TBL] [Abstract][Full Text] [Related]
12. Identification of alpha-fetoprotein-derived peptides recognized by cytotoxic T lymphocytes in HLA-A24+ patients with hepatocellular carcinoma.
Mizukoshi E; Nakamoto Y; Tsuji H; Yamashita T; Kaneko S
Int J Cancer; 2006 Mar; 118(5):1194-204. PubMed ID: 16152611
[TBL] [Abstract][Full Text] [Related]
13. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
[TBL] [Abstract][Full Text] [Related]
14. Comparison of AFP-L3 and p53 Antigen Concentration with Alpha-Fetoprotein as Serum Markers for Hepatocellular Carcinoma.
Abdel-Aziz MM; Elshal MF; Abass AT; El-Kafrawy S; Ezzat S; Abdel-Wahab M
Clin Lab; 2016; 62(6):1121-9. PubMed ID: 27468575
[TBL] [Abstract][Full Text] [Related]
15. Improved Performance of Serum Alpha-Fetoprotein for Hepatocellular Carcinoma Diagnosis in HCV Cirrhosis with Normal Alanine Transaminase.
Yang JD; Dai J; Singal AG; Gopal P; Addissie BD; Nguyen MH; Befeler AS; Reddy KR; Schwartz M; Harnois DM; Yamada H; Gores GJ; Feng Z; Marrero JA; Roberts LR
Cancer Epidemiol Biomarkers Prev; 2017 Jul; 26(7):1085-1092. PubMed ID: 28258053
[No Abstract] [Full Text] [Related]
16. A combination of α-fetoprotein, midkine, thioredoxin and a metabolite for predicting hepatocellular carcinoma.
Omran MM; Farid K; Omar MA; Emran TM; El-Taweel FM; Tabll AA
Ann Hepatol; 2020; 19(2):179-185. PubMed ID: 31648804
[TBL] [Abstract][Full Text] [Related]
17. Immunoregulation of dendritic and T cells by alpha-fetoprotein in patients with hepatocellular carcinoma.
Ritter M; Ali MY; Grimm CF; Weth R; Mohr L; Bocher WO; Endrulat K; Wedemeyer H; Blum HE; Geissler M
J Hepatol; 2004 Dec; 41(6):999-1007. PubMed ID: 15582134
[TBL] [Abstract][Full Text] [Related]
18. [Usefulness of serum alpha-fetoprotein (AFP) as a marker for hepatocellular carcinoma (HCC) in hepatitis C virus related cirrhosis: analysis of the factors influencing AFP elevation without HCC development].
Kim KA; Lee JS; Jung ES; Kim JY; Bae WK; Kim NH; Moon YS
Korean J Gastroenterol; 2006 Nov; 48(5):321-6. PubMed ID: 17132920
[TBL] [Abstract][Full Text] [Related]
19. Serum alpha-fetoprotein measurement in predicting clinical outcome related to autologous cytokine-induced killer cells in patients with hepatocellular carcinoma undergone minimally invasive therapy.
Pan CC; Huang ZL; Li W; Zhao M; Zhou QM; Xia JC; Wu PH
Chin J Cancer; 2010 Jun; 29(6):596-602. PubMed ID: 20507732
[TBL] [Abstract][Full Text] [Related]
20. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
